144 related articles for article (PubMed ID: 29973375)
1. Long-acting FC-fusion rhGH (GX-H9) shows potential for up to twice-monthly administration in GH-deficient adults.
Ku CR; Brue T; Schilbach K; Ignatenko S; Magony S; Chung YS; Kim BJ; Hur KY; Kang HC; Kim JH; Kim MS; Kowalska A; Bolanowski M; Ruchala M; Damjanovic S; Payer J; Choi YJ; Heo SJ; Kim TK; Heo M; Lee J; Lee EJ
Eur J Endocrinol; 2018 Sep; 179(3):169-179. PubMed ID: 29973375
[TBL] [Abstract][Full Text] [Related]
2. A Randomized Safety and Efficacy Study of Somavaratan (VRS-317), a Long-Acting rhGH, in Pediatric Growth Hormone Deficiency.
Moore WV; Nguyen HJ; Kletter GB; Miller BS; Rogers D; Ng D; Moore JA; Humphriss E; Cleland JL; Bright GM
J Clin Endocrinol Metab; 2016 Mar; 101(3):1091-7. PubMed ID: 26672637
[TBL] [Abstract][Full Text] [Related]
3. A Randomized Phase 2 Study of Long-Acting TransCon GH vs Daily GH in Childhood GH Deficiency.
Chatelain P; Malievskiy O; Radziuk K; Senatorova G; Abdou MO; Vlachopapadopoulou E; Skorodok Y; Peterkova V; Leff JA; Beckert M;
J Clin Endocrinol Metab; 2017 May; 102(5):1673-1682. PubMed ID: 28201598
[TBL] [Abstract][Full Text] [Related]
4. Reversible Albumin-Binding GH Possesses a Potential Once-Weekly Treatment Profile in Adult Growth Hormone Deficiency.
Rasmussen MH; Janukonyté J; Klose M; Marina D; Tanvig M; Nielsen LF; Höybye C; Andersen M; Feldt-Rasmussen U; Christiansen JS
J Clin Endocrinol Metab; 2016 Mar; 101(3):988-98. PubMed ID: 26727076
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial].
Hou L; Luo XP; Du ML; Ma HM; Gong CX; Li YC; Shen SX; Zhao ZH; Liang L; Dong GP; Yan CY; Du HW
Zhonghua Er Ke Za Zhi; 2009 Jan; 47(1):48-52. PubMed ID: 19573383
[TBL] [Abstract][Full Text] [Related]
6. Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial.
Battelino T; Rasmussen MH; De Schepper J; Zuckerman-Levin N; Gucev Z; Sävendahl L;
Clin Endocrinol (Oxf); 2017 Oct; 87(4):350-358. PubMed ID: 28656605
[TBL] [Abstract][Full Text] [Related]
7. A long-acting human growth hormone with delayed clearance (VRS-317): results of a double-blind, placebo-controlled, single ascending dose study in growth hormone-deficient adults.
Yuen KC; Conway GS; Popovic V; Merriam GR; Bailey T; Hamrahian AH; Biller BM; Kipnes M; Moore JA; Humphriss E; Bright GM; Cleland JL
J Clin Endocrinol Metab; 2013 Jun; 98(6):2595-603. PubMed ID: 23585663
[TBL] [Abstract][Full Text] [Related]
8. Pegylated long-acting human growth hormone possesses a promising once-weekly treatment profile, and multiple dosing is well tolerated in adult patients with growth hormone deficiency.
Søndergaard E; Klose M; Hansen M; Hansen BS; Andersen M; Feldt-Rasmussen U; Laursen T; Rasmussen MH; Christiansen JS
J Clin Endocrinol Metab; 2011 Mar; 96(3):681-8. PubMed ID: 21177789
[TBL] [Abstract][Full Text] [Related]
9. A low starting dose of genotropin in growth hormone-deficient adults.
Janssen YJ; Frölich M; Roelfsema F
J Clin Endocrinol Metab; 1997 Jan; 82(1):129-35. PubMed ID: 8989246
[TBL] [Abstract][Full Text] [Related]
10. Long-Acting C-Terminal Peptide-Modified hGH (MOD-4023): Results of a Safety and Dose-Finding Study in GHD Children.
Zelinska N; Iotova V; Skorodok J; Malievsky O; Peterkova V; Samsonova L; Rosenfeld RG; Zadik Z; Jaron-Mendelson M; Koren R; Amitzi L; Raduk D; Hershkovitz O; Hart G
J Clin Endocrinol Metab; 2017 May; 102(5):1578-1587. PubMed ID: 28323965
[TBL] [Abstract][Full Text] [Related]
11. Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections.
Amato G; Mazziotti G; Di Somma C; Lalli E; De Felice G; Conte M; Rotondi M; Pietrosante M; Lombardi G; Bellastella A; Carella C; Colao A
J Clin Endocrinol Metab; 2000 Oct; 85(10):3720-5. PubMed ID: 11061530
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
Chihara K; Kato Y; Kohno H; Takano K; Tanaka T; Teramoto A; Shimatsu A
Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776
[TBL] [Abstract][Full Text] [Related]
13. Skeletal effects of two years of treatment with low physiological doses of recombinant human growth hormone (GH) in patients with adult-onset GH deficiency.
Janssen YJ; Hamdy NA; Frölich M; Roelfsema F
J Clin Endocrinol Metab; 1998 Jun; 83(6):2143-8. PubMed ID: 9626153
[TBL] [Abstract][Full Text] [Related]
14. Comparative pharmacokinetics and pharmacodynamics of a new sustained-release growth hormone (GH), LB03002, versus daily GH in adults with GH deficiency.
Bidlingmaier M; Kim J; Savoy C; Kim MJ; Ebrecht N; de la Motte S; Strasburger CJ
J Clin Endocrinol Metab; 2006 Aug; 91(8):2926-30. PubMed ID: 16720652
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of LB03002, a once-weekly sustained-release human GH for 12-month treatment in Korean children with GH deficiency.
Hwang JS; Lee HS; Chung WY; Han HS; Jin DK; Kim HS; Ko CW; Lee BC; Lee DY; Lee KH; Shin JH; Suh BK; Yoo HW; Ji HJ; Lee JH; Bae YJ; Kim DH; Yang SW
Eur J Endocrinol; 2013 Aug; 169(2):179-85. PubMed ID: 23682096
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient children.
Kemp SF; Fielder PJ; Attie KM; Blethen SL; Reiter EO; Ford KM; Marian M; Dao LN; Lee HJ; Saenger P
J Clin Endocrinol Metab; 2004 Jul; 89(7):3234-40. PubMed ID: 15240597
[TBL] [Abstract][Full Text] [Related]
17. [Effect of recombinant human growth hormone on glucose metabolism in children with growth hormone deficiency].
Liang L; Zou CC; Li Y; Wang CL; Jiang YJ; Dong GP; Fu JF; Wang XM
Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):657-61. PubMed ID: 17217656
[TBL] [Abstract][Full Text] [Related]
18. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group.
Mauras N; Attie KM; Reiter EO; Saenger P; Baptista J
J Clin Endocrinol Metab; 2000 Oct; 85(10):3653-60. PubMed ID: 11061518
[TBL] [Abstract][Full Text] [Related]
19. 12-month effects of once-weekly sustained-release growth hormone treatment in adults with GH deficiency.
Biller BM; Ji HJ; Ahn H; Savoy C; Siepl EC; Popovic V; Coculescu M; Roemmler J; Gavrila C; Cook DM; Strasburger CJ
Pituitary; 2013 Sep; 16(3):311-8. PubMed ID: 22915288
[TBL] [Abstract][Full Text] [Related]
20. Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH.
Touraine P; D'Souza GA; Kourides I; Abs R; Barclay P; Xie R; Pico A; Torres-Vela E; Ekman B;
Eur J Endocrinol; 2009 Oct; 161(4):533-40. PubMed ID: 19654233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
